WHO VigiBase Analysis: Thromboembolic Safety of Tofacitinib, Baricitinib in Rheumatoid Arthritis

June 3-6, 2020; Virtual Meeting
Analysis of individual case safety reports in worldwide pharmacovigilance database examines thromboembolic events with tofacitinib and baricitinib.
Format: Microsoft PowerPoint (.ppt)
File Size: 178 KB
Released: July 1, 2020


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Related Content

Expert commentary on key studies on safety and efficacy of JAK inhibitors from EULAR 2020 as reported by CCO

Eric M. Ruderman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: July 16, 2020 Expired: July 15, 2021

Expert commentary on key studies in RA prevention and treatment from EULAR 2020 as reported by CCO

Paul Emery, MA, MD, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: July 16, 2020 Expired: July 15, 2021

From EULAR 2020, 52-week analysis of FINCH 1 trial of add-on filgotinib in rheumatoid arthritis with inadequate methotrexate response, by CCO

Released: July 13, 2020

From EULAR 2020, new safety analysis of upadacitinib use in patients with RA from 5 phase III SELECT trials

Released: July 7, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?